Skip to main content
SpringerLink
Log in

Antiretroviral Therapy in Pregnancy

A Focus on Safety

  • Practical Drug Safety
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Antiretroviral compounds differ from most other new pharmaceutical agents in that they have become widely prescribed in pregnancy in the absence of proof of safety. They are prescribed for the treatment of the mother and to reduce the risk of transmission of HIV to the fetus. In the animal models tested to date, no increased risk of malformations has been demonstrated for some compounds whereas others have been associated with malformations or developmental abnormalities in rats, mice or rabbits and, in the case of efavirenz, monkeys.

Zidovudine monotherapy is still prescribed to reduce the risk of mother-to-child transmission of HIV. Combinations of 3 or more compounds are recommended when treatment of the mother is deemed necessary because of advanced HIV infection. Until recently, in vitro toxicity studies relevant to pregnancy were restricted to single agents; no animal teratogenicity or carcinogenesis studies of combination therapy have been published.

Despite many thousands of women having taken antiretroviral therapy to reduce the risk of transmission, documented experience in human pregnancy remains sadly lacking, with the possible exception of zidovudine which has been prescribed in clinical trials to several hundred mother—infant pairs. For other compounds and for the numerous permutations of combination therapy, data are available only from small phase I/II studies, from retrospective investigations and from the prospective arm of the Antiretroviral Pregnancy Register (i.e. pregnancies in women taking antiretrovirals who were registered before delivery and then followed up).

Antiretroviral monotherapy and combination therapy is widely prescribed in pregnancy because: (i) with appropriate management,which includes antiretroviral therapy, the risk of mother-to-child transmission can be reduced from 15 to 25% to less than 1%; (ii) pregnant women with advanced HIV infection require therapy; (iii) combination therapy with at least 3 compounds significantly reduces morbidity and mortality compared with dual or monotherapy; and (iv) the benefits of therapy for both the mother and the infant outweigh the risk.

The choice of antiretroviral therapy in pregnancy may be influenced by the indication (prevention of transmission or maternal treatment), past antiretroviral therapy exposure/drug resistance, effects of pregnancy on the pharmacokinetics of the drug and factors influencing tolerability and adherence. In pregnancy, tolerability may be even more important than usual, especially if therapy exacerbates common complications of pregnancy, such as vomiting and glucose intolerance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Fig. 1
Table III
Table IV
Fig. 2
Table V

Similar content being viewed by others

References

  1. Yarchoan R, Klecker RW, Weinhold KJ, et al. Administration of 3′-azido-3′-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet 1986; I: 575–80

    Article  Google Scholar 

  2. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987; 317: 185–91

    Article  PubMed  CAS  Google Scholar 

  3. BHIVA Guidelines Co-ordinating Committee. British HIV Association Guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1997; 349: 1086–92

    Google Scholar 

  4. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994; 331: 1173–80

    Article  PubMed  CAS  Google Scholar 

  5. The Antiviral Pregnancy Registry (interim report). 1 Jan 89–31 Jan 00.Willmington (NC): Registry Project Office, 2000: 1–39

  6. Klecker RW, Collins JM, Yarchoan R, et al. Plasma and cerebrospinal fluid pharmacokinetics of 3′-azido-3′-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clin Pharmacol Ther 1987; 41: 407–12

    Article  PubMed  Google Scholar 

  7. Sieh E, Coluzzi ML, Cusella De Angelis MG, et al. The effects of AZT and DDI on pre- and postimplantation mammalian embryos: and in vivo and in vitro study. AIDS Res Hum Retroviruses 1992; 8: 639–49

    Article  PubMed  CAS  Google Scholar 

  8. Esterman AL, Rosenberg C, Brown T, et al. The effect of zidovudine and 2′,3′-dideoxyinosine on human trophoblast in culture. Pharmacol Toxicol 1995; 76: 89–92

    Article  PubMed  CAS  Google Scholar 

  9. Bawdon RE, Sobhi S, Dax J. The transfer of anti-human immunodeficiency virus nucleoside compounds by the term human placenta. Am J Obstet Gynaecol 1992; 167: 1570–4

    CAS  Google Scholar 

  10. O’Sullivan MJ, Boyer PJ, Scott GB, et al. The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women with human immunodeficiency virus and their infants: phase I acquired immunodeficiency syndrome clinical trials group (protocol 082). Zidovudine Collaborative Working Group. Am J Obstet Gynecol 1993; 168: 1510–6

    PubMed  Google Scholar 

  11. Dorenbaum A, Rodman JH, Mirochnick M, et al. Systemic pharmacokinetics (PK) of oral zidovudine (ZDV) given during labour and delivery to HIV-1 infected pregnant women. 7th Conference on Retroviruses and Opportunistic Infections; 2000 Jan 30-Feb 2; San Francisco

    Google Scholar 

  12. Rodman JH, Flynn PM, Robbins B, et al. Systemic pharmacokinetics and cellular pharmacology of zidovudine in human immunodeficiency virus type-1 infected women and newborn infants. J Infect Dis 1999; 1844–50

    Google Scholar 

  13. Poirier MC, Patterson TA, Slikker Jr W, et al. Incorporation of 3′-azido-3′-deoxythymidine (AZT) into fetal DNA and fetal tissue distribution after infusion of pregnant late-term rhesus macaques with a human-equivalent AZT dose. J Acquir Immune Defic Syndr 1999; 22: 477–83

    PubMed  CAS  Google Scholar 

  14. Oliviero OA, Shearer GM, Chougnet CAS, et al. Incorporation of zidovudine into leukocyte DNA from HIV-1-positive adults and pregnant women and cord blood from infants exposed in utero. AIDS 1999; 13: 919–25

    Article  Google Scholar 

  15. Ewings EL, Gerschenson M, St Claire MC, et al. Genotoxic and functional consequences of transplacental zidovudine exposure in fetal monkey brain mitochondria. J Acquir Immune Defic Sydnr 2000; 24: 100–5

    CAS  Google Scholar 

  16. Gerschenson M, Erhart SW, Paik CY, et al. Fetal mitochondrial heart and skeletal muscle damage in Erythrocebus patas monkeys exposed in utero to 3′-azido-3′-deoxythymidine. AIDS Res Hum Retroviruses 2000; 16: 635–44

    Article  PubMed  CAS  Google Scholar 

  17. Blanche S, Mandelbrot L, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999; 354: 1084–9

    Article  PubMed  CAS  Google Scholar 

  18. Lipshultz SL, Easley KA, Orav EJ, et al. Absence of cardiac toxicity of zidovudine in infants. N Engl J Med 2000; 343(11): 759–66

    Article  PubMed  CAS  Google Scholar 

  19. Lipshultz SL, Orav EJ, Sanders SP, et al. Cardiac structure and function in children with human immunodeficiency virus infection treated with zidovudine. N Engl J Med 1992; 327: 1260–5

    Article  PubMed  CAS  Google Scholar 

  20. Smith ME. Ongoing nucleoside safety review of HIV-exposed children in US studies. 2nd Conference on Global Strategies for prevention of HIV transmission from Mother to Infants; 1999 Sep 1–6; Montreal

    Google Scholar 

  21. Culnane M, Fowler M, Lee SS, et al. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams. JAMA 1999; 281: 151–7

    Article  PubMed  CAS  Google Scholar 

  22. Ayers KM, Clive D, Tucker W, et al. Nonclinical toxicology studies with zidovudine: genetic toxicity tests and carcinogenicity bioassays inmice and rats. Fundam Appl Toxicol 1996; 32: 148–58

    Article  PubMed  CAS  Google Scholar 

  23. Olivero OA, Anderson LM, Diwan BA, et al. Transplacental effects of 3′-azido-2′,3′-dideoxythymidine (AZT): tumorigenicity in mice and genotoxicity in mice and monkeys. J Natl Cancer Inst 1997; 89: 1602–8

    Article  PubMed  CAS  Google Scholar 

  24. Diwan BA, Riggs CW, Logsdon D, et al. Multiorgan transplacental and neonatal carcinogenicity of 3′-azido-3′-deoxythymidine in mice. Toxicol Appl Pharmacol 1999; 161: 82–9

    Article  PubMed  CAS  Google Scholar 

  25. Hanson IC, Antonelli TA, Sperling RS, et al. Lack of tumors in infants with perinatal HIV-1 exposure and fetal/neonatal exposure to zidovudine. J Acquir Immune Defic Syndr Hum Retrovir 1999; 15: 463–7

    Article  Google Scholar 

  26. Calamandrei G, Venerosi A, Branchi I, et al. Effects of prenatal zidovudine treatment on learning and memory capacities of preweanling and young adult mice. Neurotoxicology 1999; 20: 17–25

    PubMed  CAS  Google Scholar 

  27. Busidan Y, Dow-Edwards DL. Neurobehavioral effects of perinatal AZT exposure in Sprague-Dawley adult rats. Neurotoxicol Teratol 1999; 21: 359–63

    Article  PubMed  CAS  Google Scholar 

  28. Rondinini C, Venerosi A, Branchi I, et al. Long-term effects of prenatal 3′-azido-3′-deoxythymidine (AZT) exposure on intermale aggressive behaviour of mice. Psychopharmacology (Berl) 1999; 145: 317–23

    Article  CAS  Google Scholar 

  29. Busidan Y, Dow-Edwards DL. Neurobehavioral effects of perinatal AZT exposure in Sprague-Dawley weaning rats. Pharmacol Biochem Behav 1999; 64: 479–85

    Article  PubMed  CAS  Google Scholar 

  30. Fujinaga M, Schulte M, Holodniy M. Assessment of developmental toxicity of antiretroviral drugs using a rat whole embryo culture system. Teratology 2000; 62: 108–14

    Article  PubMed  CAS  Google Scholar 

  31. Metropolitan Atlanta Congenital Defects Program surveillance data, 1988-1991. Teratology 1993; 48: 695–709

    Google Scholar 

  32. Honein MA, Paulozzi LJ, Cragan JD, Correa A. Evaluation of selected characteristics of pregnancy drug registries. Teratology 1999; 60: 356–64

    Article  PubMed  CAS  Google Scholar 

  33. Sperling RS, Shapiro DE, Coombs RW, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med 1996; 335: 1621–9

    Article  PubMed  CAS  Google Scholar 

  34. Chuachoowong R, Shaffer N, Siriwasin W, et al. Short-course antenatal zidovudine reduces both cervicovaginal human immunodeficiency virus type 1 RNA levels and risk of perinatal transmission. Bangkok Collaborative Perinatal HIV Transmission Study Group. J Infect Dis 2000; 181: 99–106

    Article  PubMed  CAS  Google Scholar 

  35. Eastman PS, Shapiro DE, Coombs RW, et al. Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunodeficiency virus type 1 in pediatric AIDS Clinical Trials Group Protocol 076. J Infect Dis 1998; 177: 557–64

    Article  PubMed  CAS  Google Scholar 

  36. Clarke JR, Braganza R, Mirza A, et al. Rapid development of genotypic resistance to lamivudine when combined with zidovudine in pregnancy. J Med Virol 1999; 59: 364–8

    Article  PubMed  CAS  Google Scholar 

  37. Palumbo P, Dobbs T, Holland B, et al. Antiretroviral resistance mutations among pregnant HIV-infected women and their newborns in the US: Vertical transmission and clades [abstract]. The XIII International AIDS Conference; 2000 Jul 9-14; Durban. TuPpB1230

    Google Scholar 

  38. Sibailly TS, Ekpini E, Boni-Ouattara E, et al. Clinical course of HIV infection and surveillance for zidovudine resistance among HIV-infected women receiving short-course zidovudine therapy in Abidjan, Cote d’Ivoire [abstract]. The XIII International AIDS Conference; 2000 Jul 9-14; Durban. TuPeC3354

    Google Scholar 

  39. Kully C, Yerly S, Erb P, et al. Codon 215 mutations in human immunodeficiency virus-infected pregnant women. Swiss Collaborative’ HIV and Pregnancy’Study. J Infect Dis 1999; 179: 705–8

    Article  PubMed  CAS  Google Scholar 

  40. Welles SL, Pitt J, Colgrove RC, et al. HIV-1 genotypic zidovudine drug resistance and the risk of maternal-infant transmission in the Women and Infants Transmission Study. AIDS 2000; 14: 263–71

    Article  PubMed  CAS  Google Scholar 

  41. Bardeguez A, Mofenson LM, Shapiro D, et al. Reproductive choices and pregnancy outcomes after participation in ACTG 076. 7th Conference on Retroviruses and Opportunistic Infections; 2000 Jan 30-Feb 2; San Francisco

    Google Scholar 

  42. Roongpisuthipong A, Siriwasin W, Asavapiriyanont S, et al. Predictors of mortality in 18-month postpartum period among HIV infected women enrolled in a trial of short-course antenatal zidovudine, Bangkok, Thailand [abstract]. The XIII International AIDS Conference; 2000 Jul 9-14; Durban. TuPeB3253

    Google Scholar 

  43. Cooper ER, Nugent R, Diaz C, et al. After AIDS Clinical Trial 076: the changing pattern of zidovudine use during pregnancy, and subsequent reduction in the vertical transmission of human immunodeficiency virus in a cohort of infected women and their infants. J Infect Dis 1996; 174: 1207–11

    Article  PubMed  CAS  Google Scholar 

  44. Mayaux MJ, Teglas J-P, Mandelbrot L, et al. Acceptability and impact of zidovudine for prevention of mother-to-child human immunodeficiency virus type-1 transmission in France. J Pediatr 1997; 131: 857–62

    Article  PubMed  CAS  Google Scholar 

  45. Therapeutic and other interventions to reduce the risk of mother-to-child transmission of HIV-1 in Europe. The European Collaborative Study. Br J Obstet Gynaecol 2000; 105: 704–9

  46. Wade NA, Birkhead GS, Warren BL, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus [abstract]. N Engl J Med 1998; 339: 1409–14

    Article  PubMed  CAS  Google Scholar 

  47. Shaffer N, Chuachoowong R, Mock PA, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Lancet 1999; 353: 773–80

    Article  PubMed  CAS  Google Scholar 

  48. Lallemant M, Jourdain G, Le Coeur S, et al. Atrial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type I. N Engl J Med 2000; 343: 982–91

    Article  PubMed  CAS  Google Scholar 

  49. Wiktor S, Leroy V, Ekpini E, et al. 24 month efficacy of short-course maternal zidovudine for the prevention of mother-to-child HIV-1 transmission in a breast feeding population: a pooled analysis of two randomised clinical trials in West Africa [abstract]. The XIII International AIDS Conference; 2000 Jul 9-14; Durban. TuOrB345

    Google Scholar 

  50. Bloom SL, Dias KM, Bawdon R, et al. Thematernal-fetal transfer of lamivudine in the ex-vivo human placenta. Am J Obstet Gynecol 2000; 176: 291–3

    Article  Google Scholar 

  51. Moodley J, Moodley D, Pillay K, et al. Pharmacokinetics and antiretroviral activity of lamivudine alone or when co-administered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. J Infect Dis 1998; 178: 1327–33

    Article  PubMed  CAS  Google Scholar 

  52. Calamandrei G, Venerosi A, Branchi I, et al. Neurobehavioural effects of prenatal lamivudine (3TC) exposure in preweaning mice. Neurotoxicol Teratol 1999; 21: 365–73

    Article  PubMed  CAS  Google Scholar 

  53. Calamandrei G, Venerosi A, Branchi I, et al. Prenatal exposure to anti-HIV drugs, long-term neurobehavioral effects of lamivudine (3TC) in CD-1 mice. Neurotoxicol Teratol 2000; 22: 369–79

    Article  PubMed  CAS  Google Scholar 

  54. Pereira CM, Nosbich C, Winter HR, et al. Transplacental pharmacokinetics of dideoxyinosine in pigtailed macaques. Antimicrob Agents Chemother 1994; 38: 781–6

    Article  PubMed  CAS  Google Scholar 

  55. Pereira CM, Nosbich C, Baughman WL, et al. Effect of zidovudine on transplacental pharmacokinetics of ddI in the pigtailed macaque (Macaca nemestrina). Antimicrob Agents Chemother 1995; 39: 343–5

    Article  PubMed  CAS  Google Scholar 

  56. Odinecs A, Pereira CM, Nosbich C, et al. Prenatal and postpartum pharmacokinetics of stavudine (2′,3′-didehydro-3′-deoxythymidine) and didanosine (dideoxyinosine) in pigtailed macaques (Macaca nemestrina). Antimicrob Agents Chemother 1996; 40: 2423–5

    PubMed  CAS  Google Scholar 

  57. Wang Y, Livingston E, Patil S, et al. Pharmacokinetics of didansoine in antepartum and postpartum human immunodeficiency virus-infected women and their neonates: an AIDS Clinical Trials Group study. J Infect Dis 1999; 180: 1536–41

    Article  PubMed  CAS  Google Scholar 

  58. Toltzis P, Mourton T, Magnuson T. Comparative embryonic cytotoxicity of antiretroviral nucleosides. J Infect Dis 1994; 1690: 1100–2

    Article  PubMed  CAS  Google Scholar 

  59. Foerster M, Kastner U, Neubert R. Effect of six virustatic nucleoside analogues on the development of fetal rat thymus in organ culture. Arch Toxicol 1992; 66: 688–99

    Article  PubMed  CAS  Google Scholar 

  60. Tuntland T, Nosbich C, Baughman WL, et al. Mechanism and rate of placental transfer of zalcitabine (2′,3′-dideoxycytidine) in Macaca nemestrina. Am J Obstet Gynecol 1996; 174: 856–63

    Article  PubMed  CAS  Google Scholar 

  61. Tuntland T, Nosbich C, Unadkat J. Effect of pregnancy, mode of administration and neonatal age on the pharmacokinetics of zalcitabine (2′,3′-dideoxycytidine) in the pigtailed macaque (Macaca nemestrina). J Antimicrob Chemother 1997; 40: 687–93

    Article  PubMed  CAS  Google Scholar 

  62. Lindstrom P, Harris M, Hoberman AM, et al. Developmental toxicity of orally administered 2′,3′-dideoxycytidine in mice. Teratology 1990; 42: 131–6

    Article  PubMed  CAS  Google Scholar 

  63. Odinecs A, Nosbich C, Keller RD, et al. In vivo maternal-fetal pharmacokinetics of stavudine (2′,3′-didehydro-3′-deoxythymidine) in pigtailed macaques (Macaca nemestrina). Antimicrob Agents Chemother 1996; 40: 196–202

    PubMed  CAS  Google Scholar 

  64. Patterson TA, Binienda ZK, Newport GD, et al. Transplacental pharmacokinetics and fetal distribution of 2′,3′-didehydro-3′-deoxythymidine (d4T) and its metabolites in late-term rhesus macaques. Teratology 2000; 62: 93–9

    Article  PubMed  CAS  Google Scholar 

  65. Bawdon R. The ex vivo human placental transfer of the anti-HIV nucleoside inhibitor abacavir and the protease inhibitor amprenavir. Infect Dis Obstet Gynecol 1998; 6: 244–6

    PubMed  CAS  Google Scholar 

  66. HIV/Aids Treatment Information Service. Public Health Service Task Force recommendations for the use of Antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States [online]. Available from URL: http://hivatis.org/trtgdlns.html#Perinatal [Accessed 2001 Jul 5]

  67. Casey B, Bawdon R. Placental transfer of ritonavir with zidovudine in the ex vivo placental perfusion model. Am J Obstet Gynecol 1998; 179: 758–61

    Article  PubMed  CAS  Google Scholar 

  68. Limpongsanurak S, van Leeuwen R, Macleod C, et al. Safety, tolerability and efficacy of ritonavir in the prevention of vertical transmission. Proceedings of the 6th Conference on Retroviruses and Opportunistic Infections; 1999 Jan 31-Feb 4; Chicago

    Google Scholar 

  69. Riecke K, Schulz T, Shakibaei M, et al. Developmental toxicity of the HIV-protease inhibitor indinavir in rats. Teratology 2000; 62: 291–300

    Article  PubMed  CAS  Google Scholar 

  70. Bryson YJ, Stek A, Mirochnick M, et al. PACTG 353. A Phase I study of safety, pharmacokinetics and antiviral activity of combination nelfinavir (NFV), ZDV and 3TC in HIV-infected pregnant women and their infants. 7th Conference on Retroviruses and Opportunistic Infections; 2000 Jan 30-Feb 4; San Francisco. 715

    Google Scholar 

  71. The Antiviral Pregnancy Registry (interim report). 1 Jan 89–1 Jan 00. Willmington (NC): Registry Project Office, 2000: 96

  72. Mirochnick M, Fenton T, Gagnier P, et al. Pharmacokinetics of nevirapine in human immunodeficiency virus type-1 infected pregnant women and their neonates. J Infect Dis 1998; 178: 368–74

    Article  PubMed  CAS  Google Scholar 

  73. Musoke P, Guay LA, Bagenda D, et al. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1 infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS 1999; 13: 479–86

    Article  PubMed  CAS  Google Scholar 

  74. Taylor GP, Lyall E, Back D, et al. Pharmacological implications of prolonged in utero exposure to nevirapine. Lancet 2000; 355: 2134–5

    Article  PubMed  CAS  Google Scholar 

  75. Guay LA, Musok P, Flemin T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999; 354: 795–802

    PubMed  CAS  Google Scholar 

  76. Owor M, Deseyve M, Dueifeld C, et al. The one year safety and efficacy data of the HIVNET 012 trial. LbOr1, 16-16. 2000. XIII International AIDS Conference; 2000 Jul 9-14; Durban

    Google Scholar 

  77. Havlir D, Cheeseman SH, McLaughlin M, et al. High-dose Nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 1995; 171: 537–45

    Article  PubMed  CAS  Google Scholar 

  78. Jackson JB, Becker-Pergola G, Guay LA, et al. Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. AIDS 2000; 14: F111–F5

    Article  PubMed  CAS  Google Scholar 

  79. Jackson JB, Mracn M, Guay LA, et al. Selection of Nevirapine (NVP) resistance mutations in Ugandan women and infants receiving NVP prophylaxis to prevent HIV-1 vertical transmission (HIVNET 012). XIII International AIDS Conference; 2000 Jul 9-14; Durban

    Google Scholar 

  80. Moodley D. The SAINT Trial: Nevirapine (NVP) versus zidovudine (ZDV) + lamivudine (3TC) in prevention of peripartum HIV transmission. XIII International AIDS Conference0; 2000 Jul 9-14; Durban

    Google Scholar 

  81. Prescribing Information. Sustiva? (efavirenz) capsules: Rx only [online]. Available from URL: http://www.sustiva.com/cross_site/patientpi/aNp.Sustiva.Feb00.pdf [Accessed 2001 Jul 5]

  82. Gray G, Volaris A, McIntyre J, et al. Transplacental distribution of emivirine (EMV, Coactinon) in HIV-1 infected pregnant women and their infants: pharmacokinetics (PK) and safety. The XIII International AIDS Conference; 2000 Jul 9-14; Durban. TuPeB3255

    Google Scholar 

  83. Silverman NS, Watts DH, Hitti J, et al. Initial multicenter experience with double nucleoside therapy for human immunodeficiency virus infection during pregnancy. Infect Dis Obstet Gynecol 1998; 6: 237–43

    PubMed  CAS  Google Scholar 

  84. Blanche S, Rouzioux C, Mandelbrot L, et al. Zidovudine-lamivudine for prevention of mother to child HIV-1 transmission. 6th Conference on Retroviruses and Opportunistic Infections; 1999 Jan 31-Feb 4; Chicago

    Google Scholar 

  85. Meng Q, Walker DM, Oliviero OA, et al. Zidovudine-didanosine coexposure potentiates DNA incorporation of zidovudine and mutagenesis in human cells. Proc Natl Acad Sci U S A 2000; 97: 12667–71

    Article  PubMed  CAS  Google Scholar 

  86. Rongkavilit C, Prisuwanna P, Van Heewsijk RPG, et al. Safety and pharmacokinetics of nelfinavir when administered with stavudine and didanosine in HIV-1 exposed newborn infants. The XIII International AIDS Conference; 2000 Jul 9-14; Durban. MoPeB2188

    Google Scholar 

  87. Scott G, Shapiro DE, Scott W, et al. Safety and tolerance of ritonavir in combination with lamivudine and zidovudine in HIV-1 infected pregnant women and their infants. 6th Conference on Retroviruses and Opportunistic Infections; 1999 Jan 31-Feb 4; Chicago. 688

    Google Scholar 

  88. Blattner W, Cooper E, Charurat M, et al. Effectiveness of potent antiretroviral therapy on reducing perinatal transmission of HIV. XIII International AIDS Conference; 2000 Jul 9-14; Durban

    Google Scholar 

  89. Morris A, Zorilla C, Vajaranant M, et al. A review of protease inhibitor use in 89 pregnancies. 6th Conference on Retroviruses and Opportunistic Infections; 1999 Jan 31-Feb 4; Chicago

    Google Scholar 

  90. Lorenzi P, Spicher VM, Lauberea B, et al. Antiretroviral therapies in pregnancy: maternal, foetal and neonatal effects. AIDS 1998; 12: F241–F7

    Article  PubMed  CAS  Google Scholar 

  91. Shapiro DE, Tuomala R, Samelson R, et al. Antepartum antiretroviral therapy and pregnancy outcomes in 462 HIV-1 infected women in 1998-1999 [PACTG 367]. 7th Conference on Retroviruses and Opportunistic Infections; 2000 Jan 30-Feb 2; San Francisco

    Google Scholar 

  92. Justman J, Dancff A, Benning L, et al. Association of diabetes and protease inhibitor use in a large natural history cohort of HIV+ women. 6th Conference on Retroviruses and Opportunistic Infections; 1999 Jan 31-Feb 4;Chicago. 661

    Google Scholar 

  93. Galli L, Peruzzi M, Ballotti S, et al. Combined antiretroviral treatment, but not zidovudine monotherapy, in gestation may damage biliary epithelium in infants. The XIII International AIDS Conference; 2000 Jul 9-14; Durban. TuPeB3258

    Google Scholar 

  94. Edwards S, Larbalestier N, Hay P, et al. Experience of nevirapine (NVP) use in a London cohort of HIV infected pregnant women. HIV Medicine 2001; 2: 89–91

    Article  PubMed  CAS  Google Scholar 

  95. Johnson S, Baraboutis JG. Adverse effects associated with use of nevirapine in HIV postexposure prophylaxis for 2 health care workers. JAMA 2000; 284: 2722

    Google Scholar 

  96. Sha B, Proia L, Kessler HA. Adverse effects associated with use of nevirapine in HIV postexposure prophylaxis for 2 health care workers. JAMA 2000; 284: 2723

    PubMed  CAS  Google Scholar 

  97. Anonymous. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures - worldwide, 1997-2000.MMWR Morb Mortal Wkly Rep 2001; 49: 1153–6

  98. Benn PD, Mercey DE, Brink N, et al. Prophylaxis with a nevirapine-containing triple regimen after exposure to HIV-1. Lancet 2001; 357: 687–8

    Article  PubMed  CAS  Google Scholar 

  99. Garcia PM, Kalish LA, Pitt J, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. N Engl J Med 1999; 341: 394–402

    Article  PubMed  CAS  Google Scholar 

  100. The European Mode of Delivery Collaboration. Elective caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial. Lancet 1999 Mar 27; 353 (9158): 1035–9

  101. HIV/Aids Treatment Information Service. Adult and adolescent guidelines: guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Treatment guidelines library [online]. Available from URL: http://hivatis.org/-trtgdlns.html#adult [Accessed 2001 Jul 5]

  102. British HIV Association. Guidelines for the management of HIV infection in pregnant women and the prevention of mother to child transmission, 2001 [online]. Available from URL: http://www.aidsmap.com/about/bhiva/bhivagd.asp [Accessed 2001 Jul 5]

  103. The Antiviral Pregnancy Registry (interim report). 1 Jan 89–31 Jul 00. Willmington (NC): Registry Project Office, 2000; 11 (2): 1–55

    Google Scholar 

  104. Jungmann E, Edwards S, Booth T, et al. ART and PCP prophylaxis in early pregnancy: a highly teratogenic combination? 2nd Conference on Global Strategies for prevention of HIV transmission from Mother to Infants; 2000 Sep 1-6; Montreal

    Google Scholar 

  105. Hernandez-Diaz S, Werler MM, Walker AM, et al. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000; 343: 1608–14

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Genito-Urinary Medicine and Communicable Diseases, Imperial College School of Medicine, Norfolk Place, London, W2 1PG, England

    Graham P. Taylor & Naomi Low-Beer

Authors
  1. Graham P. Taylor
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Naomi Low-Beer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Graham P. Taylor.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Taylor, G.P., Low-Beer, N. Antiretroviral Therapy in Pregnancy. Drug-Safety 24, 683–702 (2001). https://doi.org/10.2165/00002018-200124090-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200124090-00004

Keywords

Search

Navigation